Long-term Follow-up Registry Study of Equecabtagene Autoleucel Injection

Recruiting now

Conditions studied: Multiple Myeloma

In brief

This is a multicenter, open-label, single-arm, long-term follow-up clinical study. All patients who have received Equecabtagene Autoleucel Injection treatment will be enrolled.

Key facts

Study ID

NCT07028970

Run by

Nanjing IASO Biotechnology Co., Ltd.

People needed

1500

Starts

2024-12-15

Expected to finish

2043-12-01

Last updated by the study team

2025-06-19

Who can join

Age: any. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• 1.Received Equecabtagene Autoleucel Injection treatment; 2.For those who participated in pre-marketing clinical studies or post-marketing real-world studies, must have completed or withdrawn from the original study; 3.Voluntary signing of an informed consent form approved by the ethics committee.

You may not qualify if…

• 1. Receipt of another lentiviral vector-based cell or gene therapy (either commercialized product or investigational product in a clinical tiral) between the infution of Equecabtagene Autoleucel Injection and the signing informed consent.

Where it is running

• Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences — Tianjin, China (enrolling)
• Tianjin Medical University General Hospital — Tianjin, China (enrolling)
• Peking University First Hospital — Beijing, China
• People's Hospital of Peking Universit — Beijing, China
• Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology — Wuhan, China
• Henan Cancer Hospital Affilated Cancer Hospital of Zhengzhou University — Zhengzhou, China

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.